Obesity is a major public health concern, and effective treatments are still elusive. AMP-activated protein kinase (AMPK) is a crucial regulator of energy homeostasis and has been proposed as a target for metabolic diseases, including obesity. However, most available AMPK agonists target multiple tissues to activate AMPK, which can cause adverse effects.
An Eli Lilly & Co. patent describes new relaxin receptor 1 (RXFP1; LGR7) agonists potentially useful for the treatment of diabetes, stroke, atherosclerosis and more.
One of the big questions going into the phase I readout for Metsera Inc.’s amylin analogue, MET-233i, was whether findings would support once-monthly dosing for the potential obesity candidate. They did. Results also indicated solid and dose-dependent weight loss activity, and Metsera was able to identify well-tolerated starting doses for subsequent studies, said Steve Marso, chief medical officer. “So we exceeded expectations on all three scientific objectives.”
Bioage Labs Inc. is advancing its apelin receptor (APJ) agonist programs for obesity and other indications, and has entered into an option agreement with Jikang Therapeutics to license a novel APJ agonist nanobody.
Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1 (GLP-1)/gastric inhibitory polypeptide (GIP) receptor agonist, HS-20094, for up to $2 billion.
Researchers at Chongqing Pharmaceutical Research Institute Co. Ltd. and Yaopharma Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Kexing Biopharm Co. Ltd. has announced IND clearances this month by China’s National Medical Products Administration (NMPA) and the U.S. FDA for GB-18, a biologic product for the treatment of cancer cachexia.
RSS
